While Priavoid’s oral Alzheimer’s disease drug has been shown to be safe and tolerable, it failed to have a significant impact on patients’ disease progression.
In the Phase II PRImus-AD study (NCT06182085), PRI-002 failed to show statistical improvements on the Clinical Dementia Rating – Sum of Boxes (CDR-SB) at week 48, with exploratory week 72 analysis showing a 12% slowing of decline in the modified intention-to-treat (mITT) population and 8% in the per-protocol population.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Treatment with PRI-002 was associated with a 19% slowing of cognitive decline on the Alzheimer’s Disease Assessment Scale – Cognitive Subscale, 13-item version (ADAS-Cog13) compared with placebo at week 48 in the mITT population and 23.3% in the per-protocol population.
Within the same endpoint, at the later week 72 timepoint, exploratory analyses showed a 26.7% slowing of decline in the mITT population and 35.9% in the per-protocol population, which Priavoid deemed an “encouraging signal for further investigation”.
After 48 weeks, PRI-002 showed a 7.5% difference favouring treatment over placebo on the Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL) in the mITT population and 16.9% in the per-protocol population.
This reduced at week 72 with a 1% difference favouring PRI-002 in the mITT population but increased to a 30.4% difference in the per-protocol population, suggesting a potential benefit in preserving patients’ ability to perform everyday activities.
Safety data meets endpoints
While the efficacy data was hazy, the study did meet its primary safety endpoint, with PRI-002 demonstrating a favourable safety and tolerability profile. ARIA-E (oedema) was reported as an adverse event (AE) in 2% of patients on 300mg PRI-002; 0% receiving 600mg; and 1% receiving placebo. ARIA-H (haemorrhage) was observed in 8%, 11,7% and 5% of patients, respectively.
The most commonly reported adverse events (AEs) included headache, nausea and dizziness.
The topline data were presented during the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, USA, with the full dataset, including additional safety, clinical efficacy and biomarker analyses, due to be unveiled at scientific conferences in 2027.
The study enrolled 304 patients with mild cognitive impairment or mild dementia due to Alzheimer’s who were randomised to receive oral PRI-002 at 300mg or 600mg daily, or placebo.
Professor Oliver Peters, CMO of Priavoid, said: “PRI-002 has demonstrated a favourable safety and tolerability profile, combined with a convenient oral treatment regimen. For people living with Alzheimer’s disease, a treatment that could slow cognitive and functional decline while fitting into their daily lives would contribute to quality of life.”
The company will continue to develop the drug due to the “encouraging clinical signals, favourable safety profile and preliminary biomarker findings”, positioning PRI-002 as a potentially disease-modifying therapy.
More treatment options emerging
While there are very few disease-modifying options for Alzheimer’s disease patients, consisting of just Eli Lilly’s Kisunla (donanemab) and Biogen and Eisai’s Leqembi (lecanemab), there has been some promise with other late-stage assets.
Also at CTAD, AriBio presented Phase III data for its oral drug, AR1001, which met its primary endpoint in the prespecified monotherapy population, with a 0.44-point difference between AR1001 and placebo in their clinical dementia rating sum of boxes (CDR-SB) scores – equating to a 31% slowing of clinical decline.
Lilly is also running trials of another therapy, remternetug, which has the same target as its approved therapy, while Roche is running Phase III trials of trontinemab, which is also an anti-amyloid drug, but is combined with technology to help the therapy penetrate the blood-brain barrier.
According to GlobalData analysts, across the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan, and China), the Alzheimer’s disease market is forecast to grow from $2.4bn in 2023 to $14.7bn in 2033 at a CAGR of 20%.
GlobalData is the parent company of Clinical Trials Arena.
